The first drug targeting tumor energy metabolism approved by the US Food and Drug Administration, the isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor enasidenib, also showed encouraging efficacy for treating IDH2-mutated relapsed or refractory AML (15). This evidence concerns the gene IDH2 and neoplasm.